Spanish Drug Prices to Remain Secret: Parliament Chooses Opacity Over Transparency

The Spanish Socialist Workers' Party (PSOE) and its ally SUMAR have launched a new initiative to make price agreements with pharmacy laboratories secret by law. This initiative aims to guarantee that drug prices and the conditions reached with laboratories in determining these prices are kept entirely confidential. In an interesting strategy, the bill in question is being pushed through parliament by cleverly embedding it within a broader regulation on newborn screening (neonatal screening). Thus, a critical change will be implemented away from the attention of the public and the press. The Socialist government plans to implement this opacity policy with the unexpected support of the main opposition party, the People's Party (PP).

The way the People's Party (PP) has supported this legal change constitutes one of the most striking maneuvers in recent Spanish politics. The right-wing opposition party chose to support the issue not directly on its own, but by submitting a legislative amendment proposal (enmienda) belonging to parliamentary groups. PP's submission of its own proposal in favor of the government reveals an implicit consensus between the parties regarding the pharmaceutical industry and pricing policies. Thanks to this parliamentary tactic, the controversial government proposal was made an invisible part of a broader bill. Political analysts argue that this cooperation is clear proof of how powerful the lobbying activities of pharmaceutical giants are.

The final session under which this legal change will pass will be held this Thursday in the Spanish Health Commission. The decision to emerge from the commission's vote will turn the process of hiding drug prices and purchasing conditions from the public into official law. Although officials argue that this new regulation will strengthen the state's hand in drug supply negotiations, critics interpret the situation quite differently. According to public auditors, the failure to disclose how billions of euros in public funds are spent will cause the relationship between the state and large pharmaceutical companies to become even less transparent. Thursday's vote is considered a major turning point for health policies and public spending in Spain.

This legal maneuver coincidentally comes to the agenda at a time when the Supreme Court of Spain (Tribunal Supremo) is about to announce a highly critical decision. The Supreme Court will finally conclude the long-running legal battle over whether drug prices should be public. It is thought that the government is hastily trying to pass this secrecy law upon the possibility of the court ruling in favor of disclosing prices to the public. If the law passes in parliament, the practical effect of a potential Supreme Court ruling in favor of transparency will be largely curtailed. Legal experts point out that this step taken by the legislature against the judiciary means a major setback in the struggle for administrative transparency in Spain.

Worldwide, drug prices and government subsidies have always been among controversial topics. Although governments tend to keep negotiation processes secret in order to obtain better discounts, this situation generally offends public conscience. This step taken in Spain has raised concerns that it could set a precedent for similar anti-transparency policies within the European Union. Civil society organizations and patient rights advocates emphasize that the state hiding from the public how much it pays for which drug will undermine democratic oversight. These developments stand before us as a crucial test that will clarify how the delicate balance between the management of public health expenditures and the public's right to access information will be shaped in the future.